Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 1006-1012

  Yang, Chuang ^a,b   Liu, Hai Zhong ^c   Fu, Zhong Xue ^b  

^a Third Hospital of Mianyang   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c Second Hospital of Chengdu   (China)

Author keywords

Apoptosis; Colorectal carcinoma; Cyclin; Liposomes; Oxaliplatin

Indexed keywords

CYCLIN A; CYCLIN D1; LIPOSOME; OXALIPLATIN; PEGYLATED LIPOSOMAL OXALIPLATIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN A; CYCLIN D1; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPOSOMES; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS;

EID: 84865342190     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1868     Document Type: Article

References (40)

1. Pasetto LM, D'Andrea MR, Rossi E and Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59: 159-168, 2006.
2. Lammers T, Hennink WE and Storm G: Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397, 2008.
3. Michor FJ, Iwasa Y, Lengauer C and Nowak MA: Dynamics of colorectal cancer. Semin Cancer Biol 15: 484-493, 2005.
4. Hong M, Zhu S, Jiang Y, Tang G and Pei Y: Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 133: 96102, 2009.
5. Hussain S, Plückthun A, Allen TM and Zangemeister-Wittke U: Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 6: 3019-3027, 2007.
6. Pietrangeli A, Leandri M, Terzoli E, Jandolo B and Garufi C: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56: 13-16, 2006.
7. Stern ST, Hall JB, Yu LL, Wood LJ, Paciotti GF, Tamarkin L, Long SE and McNeil SE: Translational considerations for cancer nanomedicine. J Control Release 146: 164-174, 2010.
8. Sun W, Zou W, Huang G, Li A and Zhang N: Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target 16: 357-365, 2008.
9. Allen TM, Hansen C, Martin F, Redemann C and Yau-Young A: Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066: 29-36, 1991.
10. Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP and Huang L: Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062: 142-148, 1991.
11. Tsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392, 1986.
12. Hao Z and Mak TW: Type I and type II pathways of fas-mediated apoptosis are differentially controlled by XIAP. J Mol Cell Biol 2: 63-64, 2010.
13. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
14. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
15. Jaattela M and Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol 4: 416-423, 2003.
16. Walters J, Pop C, Scott FL, Drag M, Swartz P, Mattos C, Salvesen GS and Clark AC: A constitutively active and uninhibitable caspase3 zymogen efficiently induces apoptosis. Biochem J 424: 335-345, 2009.
17. Bortner DM and Rosenberg MP: Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Cell Growth Differ 6: 1579-1589, 1995.
18. Owa T, Yoshino H, Yoshimatsu K and Nagasu T: Cell cycle regulation in the Gl phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8: 1487-1503, 2001.
19. Buolamwini JK: Cell cycle molecular targets in hovel anticancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
20. McDonald ER and El-Deiry WS: Cell cycle control as a basis for cancer drug development. Int J Oncol 16: 871-886, 2000.
21. Yang C, Liu HZ, Fu ZX and Lu WD: Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma. BMC Biotechnol 11: 1-8, 2011.
22. Yang C, Liu HZ, Lu WD and Fu ZX: PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma. Oncol Rep 25: 1621-1628, 2011.
23. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et al: XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460: 1035-1039, 2009.
24. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the cysteine residues in IκBα kinase and NF-κB(p65) by xanthohumol leads to suppression of NF-κB- regulated gene products and potentiation of apoptosis in leukemia cells. Blood 113: 2003-2013, 2009.
25. Nobili S, Checcacci D, Filippelli F, Del Buono S, Mazzocchi V, Mazzei T and Mini E: Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. J Chemother 20: 622-631, 2008.
26. Abizon D and Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 85: 6949-6953, 1988.
27. Gabizon AA: Stealth liposomes and tumor targeting: a step further in the quest for the magic bullet. Clin Cancer Res 7: 223-225, 2001.
28. Zalipsky S, Brandeis E, Newman MS and Woodle MC: Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 53: 71-74, 1994.
29. Panwar P, Pandey B, Lakhera PC and Singh KP: Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed 5: 101-108, 2010.
30. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S and Gabizon A: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrugresistance efflux pump. Clin Cancer Res 6: 1949-1957, 2000.
31. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C and Wei Y: BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One 6: e20586, 2011.
32. Pramanik KC, Boreddy SR and Srivastava SK: Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One 6: e20151, 2011.
33. Hunter T and Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
34. Santamaria D and Ortega S: Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 11: 1164-1188, 2006.
35. Viallard JF, Lacombe F, Belloc F, Pellegrin JL and Reiffers J: Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology. Cancer Radiother 5: 109-129, 2001.
36. Hsia DA, Tepper CG, Pochampalli MR, Hsia EY, Izumiya C, Huerta SB, Wright ME, Chen HW, Kung HJ and Izumiya Y: KDM8, a H3K36me2 histone demethylase that acts in the Cyclin A1 coding region to regulate cancer cell proliferation. Proc Natl Acad Sci USA 107: 9671-9676, 2010.
37. Sun PC, Tzao C, Chen BH, Liu CW, Yu CP and Jin JS: Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci 17: 76, 2010.
38. Tung JN, Chiang CC, Tsai YY, Chou YY, Yeh KT, Lee H and Cheng YW: CyclinD1 protein expressed in pterygia is associated with β-catenin protein localization. Mol Vis 16: 2733-2738, 2010.
39. Prall OW, Sarcevic B, Musgrove EA, Watts CK and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased Cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894, 1997.
40. Zhu X, Ohtsubo M, Böhmer RM, Roberts JM and Assoian RK: Adhesion-dependent cell cycle progression linked to the expression of Cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J Cell Biol 33: 391-403, 1996.